Giugliano D, Longo M, Maiorino MI, Bellastella G, Chiodini P, Solerte SB, Esposito K
A 2026 study published in The Lancet suggests that tirzepatide, a dual GLP-1 and GIP receptor agonist already approved for treatment of diabetes and obesity, could be an effective tool for fighting alcohol use disorder (AUD)
and protects auditory neurons from oxidative damage induced by H2O2 attack (Xie et al., 2004).EGCG acts through phosphatidylinositol 3-kinase (PI3K)/Akt signalling in cochlear NSCs to promote cell growth and neuronal differentiation, which can be used for the treatment of hearing loss (Zhang et al., 2016), and has an important protective mechanism against cochlear oxidative damage
Retatrutide Dosing Guide Standard titration protocols from 2mg to 12mg weekly
AOD9604 vs Intact hGH in Obesity Models A direct head-to-head comparison of AOD9604 and intact hGH in obese and lean mice confirmed that both compounds significantly reduced body weight gain in obese animals through increased fat oxidation and lipolysis stimulation but that AOD9604 achieved this without the hGH receptor binding, IGF-1 stimulation, hyperglycaemia, or reduced insulin secretion associated with full-length hGH treatment
Variants can significantly reduce your metabolic protection without you knowing